ArticleIranian journal of pharmaceutical research : IJPR2019
Sensitization of Resistance Ovarian Cancer Cells to Cisplatin by Biogenic Synthesized Silver Nanoparticles through p53 Activation.
Article in Iranian journal of pharmaceutical research : IJPR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Nanoparticles in gynecologic cancers: a bibliometric and visualization analysis.Frontiers in oncology · 2024Pooled it
- Emerging Antineoplastic Biogenic Gold Nanomaterials for Breast Cancer Therapeutics: A Systematic Review.International journal of nanomedicine · 2020Pooled it
- Iron oxide nanoparticles co-conjugated with hyaluronic acid and limonene trigger oxidative stress and cell cycle arrest in triple-negative breast cancer.Medical oncology (Northwood, London, England) · 2026Article
- Hyaluronic acid/kaempferol-functionalized Fe₃O₄ nanoparticles promote ROS-associated apoptosis and modulate caspase-8/BCRT1 axis in triple-negative breast cancer.Scientific reports · 2026Article
- Silver Nanoparticles Decorated UiO-66-NHPharmaceutics · 2025Article
- Advances in Phytonanotechnology: A Plant-Mediated Green Synthesis of Metal Nanoparticles UsingNanomaterials (Basel, Switzerland) · 2023Review
- Nanodelivery systems: An efficient and target-specific approach for drug-resistant cancers.Cancer medicine · 2023Review
- Current Trends and Prospects for Application of Green Synthesized Metal Nanoparticles in Cancer and COVID-19 Therapies.Viruses · 2023Review
- Curcumin: a natural organic component that plays a multi-faceted role in ovarian cancer.Journal of ovarian research · 2023Review
- The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer.Biomolecules · 2023Review
- Could Cisplatin Loading on Biosynthesized Silver Nanoparticles Improve Its Therapeutic Efficacy on Human Prostate Cancer Cell Line and Reduce Its In Vivo Nephrotoxic Effects?Biological trace element research · 2022Article
- Bibliometric analysis on exploitation of biogenic gold and silver nanoparticles in breast, ovarian and cervical cancer therapy.Frontiers in pharmacology · 2022Review
- Gold Nanoparticles Synthesized Using Extracts ofNanomaterials (Basel, Switzerland) · 2021Article
- HIF-1α Is a Rational Target for Future Ovarian Cancer Therapies.Frontiers in oncology · 2021Review
- Enhanced Neural Differentiation of Epidermal Neural Crest Stem Cell by Synergistic Effect of Lithium carbonate and Crocin on BDNF and GDNF Expression as Neurotrophic Factors.Iranian journal of pharmaceutical research : IJPR · 2021Article
- Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer.Cancer drug resistance (Alhambra, Calif.) · 2021Review
- Therapeutic role of curcumin and its novel formulations in gynecological cancers.Journal of ovarian research · 2020Review
- Identification of the key genes associated with chemotherapy sensitivity in ovarian cancer patients.Cancer medicine · 2020Article
- Microcellular Environmental Regulation of Silver Nanoparticles in Cancer Therapy: A Critical Review.Cancers · 2020Review
- Fungus-mediated Extracellular Biosynthesis and Characterization of Zirconium Nanoparticles Using StandardIranian journal of pharmaceutical research : IJPR · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Today, drug resistance is one of the major problems in fight against cancer. Therefore, combination of therapeutic strategies was raised to effectively improve disease prognosis. In this regard, silver nanoparticles (AgNPs) are considered significant due to their anticancer properties. This study aimed to return sensitivity to cisplatin to A2780 cisplatin-resistance cell lines in the presence of biogenic synthesis curcumin-coated silver nanoparticles (cAgNPs). Synergic cellular effects of cAgNPs and cisplatin on ovarian carcinoma 2780 resistant to cisplatin cells were assessed using MTT assay, Acridine orange (AO)/propidium iodide (PI), DAPI staining, Annexin V/PI assay, and caspase 3/9 activation assay. Finally, expression of p53 and MMP-9 genes were evaluated using semi-quantitative reverse transcription polymerase chain reaction (RT-PCR). According to the results, 8 µg/mL and 62 µg/mL of cAgNPs and cisplatin led to 50% cell death in 48 h, respectively. Therefore, we combined non-toxic concentration of nanoparticles (1-5 µg/mL) with cisplatin (2.5 µg/mL). Decreased proliferation rate was about 50% for synergic use of cisplatin (2.5 µg/mL) and cAgNPs (2 µg/mL). According to the results, cell death induction significantly increased by AO/PI, DAPI staining and Annexin V/PI assay in the combined group. Moreover, activity of caspase 3/9 significantly increased in the mentioned group. The combined use of cAgNPs and cisplatin resulted in upregulated expression of p53 gene and downregulated expression of MPP-9 gene. As observed in this study, a combination of cAgNPs and cisplatin increased the efficiency of apoptosis induction in A2780 cells, compared to the independent use of cisplatin or cAgNPs.
Indexed as
Identifiers
31089357PMC6487401W2903963989What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.